[HTML][HTML] Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis
F Fabrizi, R Cerutti, V Dixit, E Ridruejo - Nefrología (English Edition), 2021 - Elsevier
Background Hepatitis C is an important agent of liver damage in patients with chronic kidney
disease and the advent of DAAs has dramatically changed the management of HCV positive …
disease and the advent of DAAs has dramatically changed the management of HCV positive …
[HTML][HTML] Real-world effectiveness of direct-acting antiviral regimens against hepatitis C virus (HCV) genotype 3 infection: A systematic review and meta-analysis
L Zhuang, J Li, Y Zhang, S Ji, Y Li, Y Zhao, B Li, W Li… - Annals of …, 2021 - Elsevier
Patients with hepatitis C virus (HCV) genotype 3 (GT3) infection are resistant to direct-acting
antiviral (DAA) treatments. This study aimed to analyze the effectiveness of sofosbuvir …
antiviral (DAA) treatments. This study aimed to analyze the effectiveness of sofosbuvir …
Sofosbuvir and Velpatasvir combination is safe and effective in treating chronic hepatitis C in end‐stage renal disease on maintenance haemodialysis
Abstract Background & Aims There is emerging data on the use of Sofosbuvir‐based directly
acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end‐stage …
acting antiviral (DAA) drug regimens in chronic hepatitis C (CHC) patients with end‐stage …
Acute hepatitis C treatment in advanced renal failure using 8 weeks of pan-genotypic daclatasvir and reduced-dose sofosbuvir
A Goel, DS Bhadauria, A Kaul, A Verma… - Nephrology Dialysis …, 2021 - academic.oup.com
Background Sofosbuvir is not recommended in persons with estimated glomerular filtration
rate (eGFR)< 30 mL/min. We report the results of treatment with an off-label 8-week regimen …
rate (eGFR)< 30 mL/min. We report the results of treatment with an off-label 8-week regimen …
An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease
S Majd Jabbari, K Maajani, S Merat, H Poustchi… - Plos one, 2021 - journals.plos.org
Sofosbuvir seems to be a revolutionary treatment for Hepatitis C-infected patients with
advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The …
advanced chronic kidney disease (CKD) but existing evidence is not quite adequate. The …
INASL-ISN joint position statements on management of patients with simultaneous liver and kidney disease
Renal dysfunction is very common among patients with chronic liver disease, and
concomitant liver disease can occur among patients with chronic kidney disease. The …
concomitant liver disease can occur among patients with chronic kidney disease. The …